Rural generalist · free tool
Guideline Finder
The guidelines and ACRRM statements your exam answers should name: what each recommends, a sentence you can write to cite it, what changed recently and the outdated answer to avoid. Quiz yourself, flip flashcards, print a cheat sheet. Free, no sign-up.
40 guidelines · 6 from ACRRM · 16 recently changed · checked 2026-11
You know 0%
ACRRM exam guideline cheat sheet · checked 2026-11 · fellowshipready.com.au
Small rural hospital emergency departments: minimum standards: College Standards for Small Rural Hospital Emergency Departments (ACRRM, Revised December 2019). Have an appropriately trained doctor on site or on close call at all times, at least one RN on site, and a clear system for calling in extra staff. Require 24/7 access to retrieval services and in-house telehealth video, ideally from the resuscitation room, with direct-dial numbers displayed. Doctors should hold a recognised fellowship and current ALS, APLS, EMST and emergency obstetric skills certification (or equivalents). Debrief and audit serious cases with the regional referral centre, and test a mass-casualty plan at least once a year.
Telehealth in rural and remote practice: College Position Statement: Remote Consultations Using Telehealth (ACRRM, Version 2.0 (May 2022)). Telehealth adds to in-person care but cannot replace it. Physical examination remains central to diagnosis. Telehealth should strengthen the existing relationship with the usual clinician and support continuity of care. Video is preferred over phone, and funding should cover clinicians at both ends of the consultation. Safety should be judged with a risk-based framework that accounts for isolation and workforce gaps.
Rural maternity services and birthing close to home: College Position Statement: Rural and Remote Maternity Services (ACRRM, Version 1.0 (March 2026)). Women should get high-quality maternity care close to home, with continuity of care and clear escalation pathways. Each woman's care team should include a medical practitioner with obstetric training. Rural generalists are central to rural maternity care. Closing or downgrading birthing units shifts risk onto women and families through travel, relocation and loss of other services. It refers to the National Consensus Framework for Rural Maternity Services (2nd edition).
What is a rural generalist?: College Position Statement: Rural Generalist Medicine (ACRRM, Version 2.0 (July 2025)). ACRRM endorses the Collingrove Agreement definition. A rural generalist provides comprehensive general practice and emergency care, plus parts of other specialist care, in hospital and community settings. The broader Cairns Consensus scope adds inpatient care, extended procedural or cognitive skills, population health, and teamwork. Rural generalist medicine is described as a distinct, broad and clinically complex scope of practice that needs recognition, training and credentialing.
End-of-life care in rural practice: College Position Statement: End of Life Care (ACRRM, Version 3.0 (August 2025)). Rural doctors should start advance care planning conversations as patients approach end of life and revisit them as things change. Plans can be uploaded to My Health Record. Rural generalists and rural GPs are key providers of palliative care, and funding (such as dedicated MBS items) should recognise this. VAD laws differ by jurisdiction, and practitioners may be barred from raising VAD first. Commonwealth law limits discussing VAD by telehealth (carriage service). ACRRM supports reviewing this to improve rural access.
Harmful substance use in rural communities: College Position Statement: Harmful Substance Use (ACRRM, Version 2.0 (February 2024)). Treat harmful substance use as a health issue and divert people into health programs rather than the justice system. Rural generalists are often the first and only providers. Those with AOD training are well placed to coordinate care if properly funded. Alcohol is second only to tobacco as a preventable cause of death and hospitalisation. Crystal methamphetamine use is more common in rural Australia and especially harmful.
Remote primary care protocols (CARPA): CARPA Standard Treatment Manual (Remote Primary Health Care Manuals) (Remote Primary Health Care Manuals project, Flinders University, 8th edition). It is the standard protocol manual for clinicians in remote and rural Central and Northern Australia, now used more widely in remote Australia. It covers conditions that are common, high-risk, unfamiliar or dangerous, or that matter for public health, such as skin sores, ARF and STIs. It supports standardised, coordinated care where staff may not have remote-specific training. It is used alongside the Medicines Book and the Women's Business Manual.
Queensland remote practice: the PCCM: Primary Clinical Care Manual (PCCM) (Queensland Health, 12th edition (2025)). It is the reference manual for health professionals in rural, remote and isolated settings in Queensland. It gives structured clinical protocols for emergencies and common primary care presentations. The 12th edition (2025) is current, and the online version is updated, so cite the edition.
Procedural sedation by non-anaesthetists: PG09(G) Guideline on procedural sedation (ANZCA, PG09(G) (December 2023)). The guideline covers minimal and moderate sedation only. Deep sedation is outside its scope because it may progress to general anaesthesia. Requirements are based on competency, which varies with sedation depth and patient comorbidity, rather than profession. Waveform capnography is strongly recommended for moderate sedation in adults and children. The 2023 revision replaces the 2014 version and adds specific guidance for children.
Hip fracture: timing of surgery and analgesia: Hip Fracture Clinical Care Standard (Australian Commission on Safety and Quality in Health Care, 2023 (revised)). Assess pain on arrival and regularly, and use multimodal analgesia with a nerve block unless contraindicated, including before transfer from another hospital. Aim for surgery within 36 hours of first presentation to any hospital. Mobilise without weight-bearing restrictions on the day of surgery or the day after. Before discharge, do a falls and bone health assessment, with a secondary fracture prevention plan and bone protection where appropriate.
Bacterial vaginosis: is it sexually transmitted and should partners be treated?: Australian STI Management Guidelines for Use in Primary Care: Bacterial vaginosis (ASHM, Current online edition (BV partner-treatment update)). BV is now regarded as sexually transmissible, not just an imbalance of vaginal flora. For women in an ongoing male–female relationship, treat the male partner at the same time, using the regimen in the guideline. If simultaneous partner treatment is not possible, manage BV like an STI: time treatment, abstain during treatment, or use condoms. The change followed an Australian (Melbourne Sexual Health Centre) partner-treatment trial.
Acute rheumatic fever: secondary prophylaxis: The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (RHDAustralia (Menzies School of Health Research), 3.2 edition (March 2022)). Secondary prophylaxis with benzathine benzylpenicillin G is usually given every 28 days. Selected high-risk patients may need it every 21 days. In high-risk populations the Jones criteria are applied with lower diagnostic thresholds. Secondary prophylaxis is continued for a defined duration based on age and severity of heart disease. Notify ARF and RHD where required and add patients to the jurisdictional register.
Aboriginal and Torres Strait Islander preventive health checks: National Guide to preventive healthcare for Aboriginal and Torres Strait Islander people (RACGP and NACCHO, 4th edition (2024)). This is the reference for the annual health assessment (MBS item 715), organised by age and topic, with an actions-based format. Start calculator-based CVD risk assessment at age 30, and assess individual risk factors from age 18. It is developed with community-controlled health services and emphasises culturally safe, community-led care. The 4th edition was launched in November 2024 and replaces the 3rd edition.
Anaphylaxis: first-line treatment and observation: ASCIA Guidelines: Acute Management of Anaphylaxis (Australasian Society of Clinical Immunology and Allergy (ASCIA), 2023 (content updated January 2023)). Give IM adrenaline 1:1,000 at 0.01 mg/kg (maximum 0.5 mg) into the outer mid-thigh. Repeat every 5 minutes if there is no response. Lay the patient flat and do not let them stand or walk. They may sit with legs outstretched if breathing is difficult. Antihistamines and corticosteroids are not first line and must never replace or delay adrenaline. Observe for at least 4 hours after the last adrenaline dose, and overnight for severe or protracted reactions.
Sepsis: timing of antibiotics and early resuscitation: Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock (Society of Critical Care Medicine and European Society of Intensive Care Medicine, 2021). For possible septic shock or a high likelihood of sepsis, give antimicrobials ideally within 1 hour of recognition. For possible sepsis without shock, investigate quickly and give antibiotics within 3 hours if infection is still a concern. Give at least 30 mL/kg of crystalloid in the first 3 hours for hypoperfusion, preferring balanced crystalloids. Use noradrenaline first line, with a MAP target of 65. Do not use qSOFA on its own as a screening tool.
Acute low back pain: imaging and medicines: Low Back Pain Clinical Care Standard (Australian Commission on Safety and Quality in Health Care, 2022). Assess for serious or specific pathology and screen for psychosocial factors early. Reserve imaging for suspected serious or specific pathology. Encourage staying active and returning to usual activities, including work. Use medicines to enable activity. Avoid anticonvulsants, benzodiazepines and antidepressants for low back pain. Consider opioids only in carefully selected patients, at the lowest dose for the shortest time.
Knee and hip osteoarthritis: what to avoid: Guideline for the management of knee and hip osteoarthritis (RACGP, 2nd edition (2018)). Non-drug management, such as exercise and weight management, should be optimised first. Oral NSAIDs, including COX-2 inhibitors, get a conditional recommendation for: lowest effective dose, short trial, and monitoring of GI, renal and CV harms. Paracetamol is neutral (neither for nor against). The average benefit is too small to be clinically meaningful. There is a strong recommendation against oral and transdermal opioids.
Bronchiolitis: what not to do and when to give oxygen: Australasian Bronchiolitis Guideline: 2025 Update (PREDICT Network, 2025). Diagnosis is clinical. Routine chest X-ray, bloods and viral testing are not recommended. Do not routinely use salbutamol, adrenaline, corticosteroids, hypertonic saline, antibiotics or chest physiotherapy. Consider oxygen if SpO2 stays below 90% (infants 6 weeks or older) or below 92% (under 6 weeks, or with an underlying condition). If oral intake is poor, nasogastric fluids are preferred. New in 2025: guidance on RSV prevention, including nirsevimab and maternal RSV vaccination.
Allergy prevention: introducing peanut and egg: ASCIA Guidelines: Infant Feeding and Allergy Prevention (Australasian Society of Clinical Immunology and Allergy (ASCIA), 2020 (format updated 2024)). Start solids at around 6 months, but not before 4 months, while breastfeeding continues. Introduce peanut, cooked egg, dairy and wheat in the first year, including for high-risk infants. Do not delay them. Partially or extensively hydrolysed formula is not recommended to prevent allergy.
Vaccines in pregnancy: pertussis, influenza and RSV: The Australian Immunisation Handbook (ATAGI / Australian Government Department of Health, Digital edition (continuously updated)). Influenza vaccine can be given at any stage, in every pregnancy. Give dTpa (pertussis) at 20–32 weeks in every pregnancy. If missed, it can still be given later. A dose given at 13–20 weeks does not need repeating. Maternal RSV vaccine (Abrysvo) is recommended from 28 weeks' gestation. Live vaccines are contraindicated in pregnancy.
Rh D immunoglobulin after early pregnancy loss: Guideline for the prophylactic use of Rh D immunoglobulin in pregnancy care (National Blood Authority, 2024). Check blood group and antibody screen early in pregnancy, no later than 10 weeks. A Rh D negative woman without preformed anti-D should get 250 IU after miscarriage, termination, ectopic or molar pregnancy, or CVS in the first 12 weeks. Routine use after medical termination before 10 weeks is not supported by the evidence and is left to clinical discretion. If gestational age is uncertain, consider giving Rh D Ig and arranging an ultrasound to confirm dates.
Menopausal hormone therapy: choosing a regimen: AMS Guide to MHT/HRT Doses (Australia) (Australasian Menopause Society, Information sheet (2024, March 2025 revision)). Use cyclic MHT in perimenopause or within 12 months of the last period. Use continuous combined MHT after 12 months without a period. Anyone with a uterus who takes systemic oestrogen needs a progestogen or a levonorgestrel IUD. Vaginal oestrogen alone does not need a progestogen. On continuous combined therapy, investigate bleeding that continues after the first 6 months.
Cervical screening, self-collection and post-coital bleeding: National Cervical Screening Program clinical guidelines (Cancer Council Australia (endorsed by RACGP and RANZCOG), Current online guidelines (universal self-collection since July 2022)). Asymptomatic people with a cervix aged 25–74 have an HPV test every 5 years. It can be self-collected or clinician-collected, with equal accuracy. HPV 16/18 means referral for colposcopy. Other HPV types found on a self-collected sample need a clinician-collected LBC. Symptoms such as post-coital or other unexplained bleeding follow the diagnostic pathway with a clinician-collected co-test, not routine screening or self-collection. People aged 70–74 with a negative HPV test can exit the program.
Asthma: initial treatment in adults and adolescents: Australian Asthma Handbook (National Asthma Council Australia, Version 3.0 (2025)). For people aged 12 and over, everyone with asthma should be on an inhaled corticosteroid. SABA alone is no longer recommended. As-needed budesonide–formoterol is the recommended first-line treatment after diagnosis, and anti-inflammatory relievers are preferred over SABA relievers. For diagnosis, FeNO testing is now recommended alongside spirometry for children aged 6–11 and for adolescents and adults. Refer to a specialist if asthma remains uncontrolled on a medium-dose ICS regimen.
COPD: spirometry for diagnosis and stepwise management: The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease (Lung Foundation Australia and Thoracic Society of Australia and New Zealand, Version 2.78 (December 2025)). Diagnosis requires spirometry showing a post-bronchodilator FEV1/FVC below 0.7. Do not diagnose COPD on symptoms or imaging alone. Treatment is stepwise: a short-acting reliever, then long-acting bronchodilators (LAMA and/or LABA). Add an ICS mainly for people with repeated exacerbations. Smoking cessation, vaccination and pulmonary rehabilitation are core non-drug treatments, with rehabilitation especially after an exacerbation. COPD-X is updated as a living guideline, so cite the version number.
Type 2 diabetes: targets and drug choices in general practice: Management of type 2 diabetes: A handbook for general practice (RACGP, 2024 edition (published November 2024; updated 2025)). The general HbA1c target is 7% (53 mmol/mol) or below, individualised to the person. BP: the general target is 140/90 or below, and below 130/80 with CKD. In secondary prevention, aim for LDL below 1.4 mmol/L and at least a 50% reduction. Metformin remains the usual first drug. SGLT2 inhibitors and GLP-1 receptor agonists are chosen for their heart and kidney benefits in people with CVD, CKD or heart failure. RSV vaccination for people over 60 is now listed as recommended.
Chronic kidney disease: detection and management in primary care: Chronic Kidney Disease (CKD) Management in Primary Care (Kidney Health Australia, 5th edition (2024)). Test at-risk adults (diabetes, hypertension, CVD, family history, smoking, obesity, First Nations people aged 18 and over) with eGFR, urine ACR and BP. CKD is staged on both eGFR and albuminuria, so always order a urine ACR as well as eGFR. The 5th edition sets out a stepwise approach to lowering albuminuria and medicines that slow CKD progression and reduce CV risk, including ACE inhibitors or ARBs and SGLT2 inhibitors. It includes revised algorithms for detection and nephrology referral, the Aus CVD Risk Calculator in CKD, and guidance on culturally safe kidney care.
Cardiovascular risk assessment: who, when and which calculator: Australian guideline for assessing and managing cardiovascular disease risk (with the Aus CVD Risk Calculator) (Heart Foundation-led national guideline (Australian Chronic Disease Prevention Alliance), 2023). Assess people without known CVD: everyone aged 45–79, people with diabetes aged 35–79, and First Nations people aged 30–79. First Nations people aged 18–29 should have their individual risk factors assessed. Estimated 5-year risk: high is 10% or more, intermediate is 5% to under 10%, and low is under 5%. Risk can be reclassified up or down for ethnicity, coronary artery calcium score, family history, eGFR/uACR and severe mental illness.
Hypertension: confirming diagnosis, first-line drugs and targets: Guideline for the diagnosis and management of hypertension in adults (National Heart Foundation of Australia, 2016). If clinic BP is 140/90 or higher, confirm it with ambulatory or home BP monitoring. First-line drugs are an ACE inhibitor or ARB, a calcium channel blocker, or a thiazide diuretic. Beta-blockers are not first line for uncomplicated hypertension, and an ACE inhibitor should not be combined with an ARB. Target below 140/90 in uncomplicated hypertension. A systolic target below 120 can be considered in selected high-risk patients, with close monitoring. Base treatment decisions on absolute CVD risk as well as the BP level.
Heart failure with reduced ejection fraction: the four pillars: Consensus statement on the current pharmacological prevention and management of heart failure (Australian expert consensus (Sindone et al., Medical Journal of Australia), 2022 (MJA 217(4))). In HFrEF, start four drug classes early rather than one at a time: an ARNI (preferred) or ACE inhibitor, a beta-blocker, an MRA, and an SGLT2 inhibitor. Use an ACE inhibitor instead of an ARNI if hypotension is a problem, and consider switching to an ARNI later. Start the beta-blocker once a congested patient is euvolaemic, and titrate all four classes to the maximum tolerated dose. Dapagliflozin or empagliflozin is recommended across all types of heart failure, including HFpEF.
Minor stroke and high-risk TIA: dual antiplatelet therapy: Australian and New Zealand Living Clinical Guidelines for Stroke Management (Stroke Foundation, Living guideline (continuously updated)). For minor ischaemic stroke or high-risk TIA, start aspirin plus clopidogrel within 24 hours and continue short term (about 3 weeks). This is a strong recommendation. Ticagrelor plus aspirin for 30 days is an alternative. Assess and image TIA and minor stroke urgently, because early stroke risk is highest in the first days. This is a living guideline, so cite it as the current online version.
Palliative care in rural practice: anticipatory medicines and deprescribing: Therapeutic Guidelines: Palliative Care (Therapeutic Guidelines Ltd, 2024 update (published December 2024)). Bring in palliative care early, alongside disease-modifying treatment, with care planned around the person's goals and prognosis. Start deprescribing early, using shared decision-making. Anticipatory prescribing for the last days of life uses drugs available on the PBS Prescriber Bag. DOACs are acceptable for treating VTE in palliative patients. VTE prophylaxis is generally not recommended in the last weeks of life.
Dementia: cholinesterase inhibitors and antipsychotics: Clinical Practice Guidelines and Principles of Care for People with Dementia (NHMRC Partnership Centre for Dealing with Cognitive and Related Functional Decline in Older People (NHMRC-approved), 2016). Use non-drug approaches first for BPSD, and look for and treat pain. Cholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine can be used in mild to moderate Alzheimer disease. They should not be prescribed for mild cognitive impairment. Avoid antipsychotics for mild to moderate BPSD because they raise the risk of stroke and death. They may be offered for severe distress or risk to others. Review antipsychotics every 4–12 weeks and consider stopping them.
Delirium: screening and the limited role of antipsychotics: Delirium Clinical Care Standard (Australian Commission on Safety and Quality in Health Care, 2021 (revised)). The standard has eight quality statements covering screening, assessment, prevention, management and follow-up. Screen people at risk (for example, older people or those with cognitive impairment) for delirium when they present. Prevention and management rely on non-drug, multicomponent strategies. Antipsychotics are not routinely used to prevent or treat delirium. Use them only for severe distress or risk, at the lowest dose for the shortest time.
Medically unstable eating disorders: risk and refeeding: Medical emergencies in eating disorders (MEED): Guidance on recognition and management (CR233) (Royal College of Psychiatrists (UK), CR233 (May 2022)). MEED replaces the MARSIPAN reports (CR189 and CR168) with one guidance document covering all ages. Assess medical risk across several domains (BMI or %median BMI, rate of weight loss, cardiovascular signs, ECG, bloods, muscle strength) using its risk summary tables. Prevent refeeding syndrome by monitoring and correcting electrolytes, and avoid underfeeding, which also causes harm. Includes annexes on type 1 diabetes and eating disorders and summary sheets for assessment.
First-episode psychosis: early intervention: Australian Clinical Guidelines for Early Psychosis (Orygen, 2nd edition (updated)). Duration of untreated psychosis is a risk factor for poor outcome that can be changed. Early detection and timely, comprehensive treatment are central. Early intervention can reduce distress, may improve short-term outcomes, and is considered cost-effective. Intervening in the at-risk (putative prodromal) phase may help prevent the onset of psychosis. Care for young people should be comprehensive and youth-focused, including psychosocial and family support as well as medication.
Alcohol use disorder: withdrawal and relapse-prevention drugs: Guidelines for the Treatment of Alcohol Problems (Australian Government-funded expert guideline (Haber et al., University of Sydney), 2021). Use the AUDIT to screen in primary care and hospitals. AUDIT-C is an alternative for community screening. Most withdrawal can be managed as an outpatient with support, using a tapering diazepam regimen with staged daily supply. Acamprosate helps maintain abstinence and naltrexone prevents relapse to heavy drinking (both Level A). Disulfiram is only for supervised, motivated patients. Baclofen and topiramate (off-label) have some evidence but should not be first line.
Suspected melanoma: biopsy and referral: Optimal care pathway for people with melanoma (Cancer Council Australia (Optimal Care Pathways), 2nd edition (2021)). If melanoma is suspected, do an excisional biopsy of the whole lesion with a 2 mm margin, or refer. Once histology confirms melanoma, re-excise with the recommended margins. Discuss sentinel lymph node biopsy for melanomas thicker than 1 mm, or thicker than 0.75 mm with high-risk features such as ulceration.
Lung cancer screening: eligibility for low-dose CT: National Lung Cancer Screening Program (Australian Government Department of Health, Program guidelines (2025)). Eligible people are aged 50–70, have no symptoms of lung cancer, currently smoke or quit within the past 10 years, and have at least 30 pack-years. The screening test is low-dose CT, and every scan needs a new request. Next steps follow the risk category in the radiology report: rescreen in 24, 12, 6 or 3 months, or refer to a respiratory physician or lung cancer MDT. Symptomatic patients need diagnostic investigation, not screening.
Bowel cancer screening from age 45: National Bowel Cancer Screening Program (Australian Government Department of Health, Eligible ages 45–74 (45–49 from 1 July 2024)). The program screens people aged 45–74 with a free iFOBT every 2 years. People aged 45–49 can request their first kit. People aged 50–74 receive kits automatically by mail. The test uses two samples from different bowel motions. A positive result needs referral for colonoscopy. This program is for asymptomatic people. Symptomatic patients need diagnostic investigation.
Summaries are written in our own words from each guideline's official page and are for exam study, not clinical use. Guidelines change: check the source before you rely on it.
Try 20 free questions.
ACRRM-style questions, marked with a reason for every option. Free account, no card.
Also free: Anatomy Scroller · ACRRM exam guides